Hematologic Involvement as a Predictor of Mortality in COVID-19 Patients in a Safety Net Hospital

Gonzalez-Mosquera, Luis F.; Gomez-Paz, Sandra; Lam, Eric; Cardenas-Maldonado, Diana; Fogel, Joshua; Adi, Vishnu; Rubinstein, Sofia

doi:10.17161/kjm.vol15.15699

Cited by 4 publications

(6 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Regulatory mechanisms of neutrophil activation and changes in lung function continue to be the subject of active study [ 25 ]. Increased levels of neutrophils in the circulating blood are one of the most important signs of inflammation in COVID-19 [ 68 , 69 , 70 ]. Thus, an increase in the level of these cells in the circulation in conjunction with some other routine clinical tests allows us to distinguish patients in critical condition from patients with a severe course of the disease already in the early stages of the development of infection.…”

Section: Immunologic Features Of Bronchial Asthma Developmentmentioning

confidence: 99%

Bronchial Asthma and COVID-19: Etiology, Pathological Triggers, and Therapeutic Considerations

Starshinova,

Borozinets,

Kulpina

et al. 2024

Pathophysiology

View full text Add to dashboard Cite

Bronchial asthma (BA) continues to be a difficult disease to diagnose. Various factors have been described in the development of BA, but to date, there is no clear evidence for the etiology of this chronic disease. The emergence of COVID-19 has contributed to the pandemic course of asthma and immunologic features. However, there are no unambiguous data on asthma on the background and after COVID-19. There is correlation between various trigger factors that provoke the development of bronchial asthma. It is now obvious that the SARS-CoV-2 virus is one of the provoking factors. COVID-19 has affected the course of asthma. Currently, there is no clear understanding of whether asthma progresses during or after COVID-19 infection. According to the results of some studies, a significant difference was identified between the development of asthma in people after COVID-19. Mild asthma and moderate asthma do not increase the severity of COVID-19 infection. Nevertheless, oral steroid treatment and hospitalization for severe BA were associated with higher COVID-19 severity. The influence of SARS-CoV-2 infection is one of the protective factors. It causes the development of severe bronchial asthma. The accumulated experience with omalizumab in patients with severe asthma during COVID-19, who received omalizumab during the pandemic, has strongly suggested that continued treatment with omalizumab is safe and may help prevent the severe course of COVID-19. Targeted therapy for asthma with the use of omalizumab may also help to reduce severe asthma associated with COVID-19. However, further studies are needed to prove the effect of omalizumab. Data analysis should persist, based on the results of the course of asthma after COVID-19 with varying degrees of severity.

show abstract

Section: Immunologic Features Of Bronchial Asthma Developmentmentioning

confidence: 99%

Bronchial Asthma and COVID-19: Etiology, Pathological Triggers, and Therapeutic Considerations

Starshinova,

Borozinets,

Kulpina

et al. 2024

Pathophysiology

View full text Add to dashboard Cite

show abstract

“…Recent studies have observed a significant rise in neutrophil count among patients with COVID-19 [ 5 , 14 , 15 ]. Chen et al [ 16 ] reported that severe or critical COVID-19 patients had notably higher neutrophil counts upon admission than mild/moderate COVID-19 patients.…”

Section: Neutrophils and Covid-19mentioning

confidence: 99%

Neutrophils in COVID-19: recent insights and advances

Zhang

et al. 2023

Virol J

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19) is an acute respiratory disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which can lead to acute respiratory distress syndrome (ARDS), multi-organ failure and death, posing significant threat to human health. Studies have found that pathological mechanisms, such as cytokine storms caused by uncontrolled innate immune system activation, release of damage-associated molecular patterns during tissue injury and a high incidence of thrombotic events, are associated with the function and dysfunction of neutrophils. Specifically, the increased formation of low-density neutrophils (LDNs) and neutrophil extracellular traps (NETs) has been shown to be closely linked with the severity and poor prognosis in patients with COVID-19. Our work focuses on understanding the increased number, abnormal activation, lung tissue infiltration, and elevated neutrophil-to-lymphocyte ratio in the pathogenesis of COVID-19. We also explore the involvement of NETs and LDNs in disease progression and thrombosis formation, along with potential therapeutic strategies targeting neutrophil and NETs formation.

show abstract

“…Early hematological abnormalities in COVID-19 patients have also been associated with an elevated risk of mortality [8,9]. As for the hematological changes that may reflect the high severity, studies have shown that platelet counts, leukocytes, lymphocytes, hemoglobin, acute phase proteins such as ferritin and C-reactive protein, in addition to irregularities in the elements of coagulation cascade and fibrin degradation products such as D-dimer, were found in patients with severe COVID-19, as well as being associated with disease progression [10,11].…”

Section: Hematological Alterations In Covid-19mentioning

confidence: 99%

Hematological Alterations Associated with COVID-19 Severe

Guimarães¹

2023

IJCICR

View full text Add to dashboard Cite

Since the onset of the COVID-19 pandemic in 2020, several studies have been relating the severity of the disease with hematological and coagulation changes besides a strong immune response. Understanding what these changes are, in addition to seeking predictive biomarkers of mortality, has become an essential task to help control and reduce the death rate during hospitalization of COVID-19 patients with a severe clinical conditions. The objective of this study was to evaluate the hematological alterations according to the clinical outcomes of COVID-19. Hematological alterations such as lymphopenia, leukocytosis, neutrophilia, and decrease in hemoglobin and red blood cells, in addition to a state of hypercoagulability and cytokine storm, have become the main alterations present in hospitalized patients with COVID-19. The initial identification of these abnormalities is useful for the early prognosis of individuals who may die during hospitalization and thus allow these patients to receive targeted support to improve their clinical condition.

show abstract

Hematologic Involvement as a Predictor of Mortality in COVID-19 Patients in a Safety Net Hospital

Cited by 4 publications

References 50 publications

Bronchial Asthma and COVID-19: Etiology, Pathological Triggers, and Therapeutic Considerations

Bronchial Asthma and COVID-19: Etiology, Pathological Triggers, and Therapeutic Considerations

Neutrophils in COVID-19: recent insights and advances

Hematological Alterations Associated with COVID-19 Severe

Contact Info

Product

Resources

About